{Reference Type}: Case Reports
{Title}: A case series of persistent lymphopaenia following treatment with fumaric acid esters for psoriasis.
{Author}: Beatty PE;Killion L;Callaghan G;Tierney E;Kelly G;Tobin AM;
{Journal}: J Clin Pharm Ther
{Volume}: 46
{Issue}: 3
{Year}: Jun 2021
{Factor}: 2.145
{DOI}: 10.1111/jcpt.13354
{Abstract}: <B>OBJECTIVE: </B>Fumaric acid esters (FAEs) have been used for fifty years to treat moderate-to-severe psoriasis. However, recent case reports of progressive multifocal leukoencephalopathy, associated with FAE-induced lymphopaenia, have been a cause for concern (J Dtsch Dermatol Ges. 2009;7:603).<BR><B>METHODS: </B>We report six cases of persistent lymphopaenia following cessation of treatment with FAEs, with a mean duration of lymphopaenia of 33 months.<BR><B>CONCLUSIONS: </B>Given the lack of evidence regarding expected recovery of lymphocyte counts, further research is required to guide physicians in the risk stratification of patients prior to considering treatment with FAEs.